STOCK TITAN

CryoPort (CYRX) DEF 14A Filings

CYRX NASDAQ

Here are the DEF 14A proxy statements from CryoPort, Inc. (CYRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CYRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYRX filings page.

Rhea-AI Summary

Cryoport, Inc. is asking stockholders to approve six director nominees, ratify Deloitte & Touche as auditor, approve executive pay on an advisory basis, and amend its 2018 Omnibus Equity Incentive Plan to add 4,275,000 shares and extend the plan to the tenth anniversary of the 2026 meeting.

In 2025, Cryoport generated $176.2 million in revenue, up 12% year over year. Commercial Cell & Gene Therapy revenue rose to $33.4 million and clinical trial revenue to $47.1 million, while Life Sciences Services reached $96.5 million, about 55% of total revenue. Management forecasts 2026 revenue of $190–$194 million and highlights a growing pipeline of expected therapy approvals and regulatory filings.